SK Chemicals’ hemophilia treatment, AFSTYLA, approved by EMA

Published: 2017-01-12 13:55:19

Updated: 2017-01-12 13:55:19

SK Chemicals(CEO Man-Hoon Park) announced, on the 10^th, the hemophilia treatment ‘AFSTYLA’ acquired the final commercialization approval from the European Medicines Agency(EMA). Thus, AFSTYLA becomes the first drug entered in the EU as a biomedicine developed by Korean technology.

CSL has carried out manufacturing, global clinical trials and approval application for AFSTYLA, developed by SK Ch...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.